Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.